Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Historical treatment-oriented fixed-combination table. Do not apply this renal interval to HIV PrEP or to tenofovir alafenamide combinations.
Check source scope before reading a dose
NIH adult ARV table: Emtricitabine/TDF
Product / population
Adults with HIV; product-specific renal recommendations.
Renal method
CrCl (mL/min), usually Cockcroft-Gault.
Source revision
Not established
Retrieved
2026-09-05
Local review status
Source-read local summary; source-specific recommendations are not automatically interchangeable.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
TRUVADA: treatment interval reduction is not a PrEP strategy
The selected product source has different renal restrictions for treatment and prevention. Its treatment table also identifies ideal (lean) body weight.
What to reconcile: Confirm indication and source-defined clearance method before selecting an interval; do not transfer the treatment-only reduced-frequency regimen to PrEP.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.